Horizon was founded by Dr Chris Torrance and Professor Alberto Bardelli in 2007 when they came across an impressive gene editing platform, rAAV, which enabled the ability to tailor-make cell lines with virtually any genomic modification. Since teaming up in September 2007 with current CEO and President Research Biotech, Dr Darrin M Disley and President Products Dr Paul Morrill, the company has grown rapidly, with offices in the UK, Europe and the U.S., and now supplies advanced research tools and expert services to over 1,400 organizations engaged in genomics research and the development of personalized medicines around the world, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers.
Horizon’s offerings are built around our proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Based from that launch pad, Horizon now offers over 23,000 catalog products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used directly by customers of by Horizon on their behalf to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.
In addition, Horizon provides rAAV, ZFN and CRISPR custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, contract research and custom screening services including for target identification and validation, and for drug combination studies.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.